Document is current
Any future updates will be listed below
-
Authors
Zheng, Qi-Jian
Wang, Hong-Hao
Ding, Chao
Han, Guang
Li, Li
Cui, Xiao-Li
Zhang, Shao-Kai
Yang, Hong-Ying
Wang, Yan
Zhang, Yong-Zhen
Wang, Wen-Jun
Hong, Yu-Ting
Yuan, Mei-Wen
Zhao, Xue-Lian
Hu, Shang-Ying
Wang, Jun-Ling
Zhao, Fang-Hui https://orcid.org/0000-0001-9294-0005
-
Funding
Funding for this research was provided by:
Merck grant (MIISP#59476)
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS 2021-I2M-1-004)
- License Information
-
More Information
Article History
Received: 5 January 2025
Accepted: 27 June 2025
First Online: 18 July 2025
Declarations
:
: The project was approved by the Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (approval number: NCCC20/041-2237). Informed consent was waived for patients who had completed treatment as part of the retrospective analysis. However, Informed consent was obtained from patients still undergoing treatment at the beginning of the study. The study was performed following the Declaration of Helsinki.
: Not applicable.
: Merck, one of the funders of this grant, is involved in the HPV vaccine business.
